Compton Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-15,931
| Closed | -$650K | – | 37 |
|
|
2023
Q1 | $650K | Sell |
15,931
-26,280
| -62% | -$1.14M | 1.4% | 19 |
|
|
2022
Q4 | $2.16M | Sell |
42,211
-6,185
| -13% | -$297K | 1.56% | 22 |
|
|
2022
Q3 | $2.12M | Sell |
48,396
-1,881
| -4% | -$91.4K | 1.42% | 22 |
|
|
2022
Q2 | $2.64M | Sell |
50,277
-13,614
| -21% | -$694K | 1.45% | 20 |
|
|
2022
Q1 | $3.31M | Buy |
63,891
+300
| +0.5% | +$15.6K | 0.92% | 26 |
|
|
2021
Q4 | $3.75M | Sell |
63,591
-73
| -0.1% | -$3.62K | 0.98% | 24 |
|
|
2021
Q3 | $2.74M | Sell |
63,664
-634
| -1% | -$28.1K | 0.8% | 33 |
|
|
2021
Q2 | $2.52M | Sell |
64,298
-360
| -0.6% | -$14K | 0.74% | 40 |
|
|
2021
Q1 | $2.34M | Buy |
64,658
+2,400
| +4% | +$85.2K | 0.73% | 42 |
|
|
2020
Q4 | $2.29M | Buy |
62,258
+4,569
| +8% | +$168K | 0.78% | 38 |
|
|
2020
Q3 | $2.01M | Buy |
57,689
+1,617
| +3% | +$56.7K | 0.77% | 37 |
|
|
2020
Q2 | $1.74M | Buy |
56,072
+264
| +0.5% | +$8.97K | 0.73% | 43 |
|
|
2020
Q1 | $1.73M | Buy |
55,808
+1,349
| +2% | +$46K | 0.85% | 39 |
|
|
2019
Q4 | $2.02M | Sell |
54,459
-1,107
| -2% | -$39.4K | 0.78% | 45 |
|
|
2019
Q3 | $1.89M | Sell |
55,566
-1,054
| -2% | -$38.3K | 0.8% | 45 |
|
|
2019
Q2 | $2.33M | Sell |
56,620
-527
| -0.9% | -$20.9K | 0.99% | 34 |
|
|
2019
Q1 | $2.3M | Buy |
57,147
+1,660
| +3% | +$66.5K | 1% | 32 |
|
|
2018
Q4 | $2.3M | Sell |
55,487
-3,162
| -5% | -$131K | 1.1% | 27 |
|
|
2018
Q3 | $2.45M | Sell |
58,649
-158
| -0.3% | -$6.08K | 0.97% | 34 |
|
|
2018
Q2 | $2.02M | Sell |
58,807
-197
| -0.3% | -$6.73K | 0.86% | 41 |
|
|
2018
Q1 | $1.99M | Sell |
59,004
-785
| -1% | -$27K | 0.84% | 42 |
|
|
2017
Q4 | $2.06M | Buy |
59,789
+2,630
| +5% | +$89.7K | 0.88% | 40 |
|
|
2017
Q3 | $1.94M | Sell |
57,159
-1,160
| -2% | -$37.3K | 0.87% | 39 |
|
|
2017
Q2 | $1.86M | Sell |
58,319
-329
| -0.6% | -$10.4K | 0.85% | 39 |
|
|
2017
Q1 | $1.9M | Buy |
58,648
+209
| +0.4% | +$6.59K | 0.93% | 35 |
|
|
2016
Q4 | $1.8M | Sell |
58,439
-54,803
| -48% | -$1.67M | 0.94% | 36 |
|
|
2016
Q3 | $3.71M | Buy |
113,242
+57,385
| +103% | +$1.92M | 1.03% | 30 |
|
|
2016
Q2 | $1.87M | Buy |
55,857
+53
| +0.1% | +$1.69K | 1.04% | 31 |
|
|
2016
Q1 | $1.57M | Buy |
55,804
+316
| +0.6% | +$9.03K | 0.88% | 33 |
|
|
2015
Q4 | $1.7M | Buy |
55,488
+474
| +0.9% | +$14.9K | 0.96% | 32 |
|
|
2015
Q3 | $1.64M | Buy |
55,014
+3,953
| +8% | +$127K | 0.59% | 31 |
|
|
2015
Q2 | $1.62M | Sell |
51,061
-211
| -0.4% | -$6.88K | 0.89% | 32 |
|
|
2015
Q1 | $1.69M | Sell |
51,272
-2,008
| -4% | -$63.8K | 0.94% | 30 |
|
|
2014
Q4 | $1.57M | Buy |
53,280
+3,505
| +7% | +$101K | 0.86% | 34 |
|
|
2014
Q3 | $1.4M | Sell |
49,775
-422
| -0.8% | -$11.8K | 0.76% | 39 |
|
|
2014
Q2 | $1.41M | Sell |
50,197
-448
| -0.9% | -$12.8K | 0.76% | 42 |
|
|
2014
Q1 | $1.54M | Sell |
50,645
-843
| -2% | -$25.1K | 0.89% | 33 |
|
|
2013
Q4 | $1.5M | Sell |
51,488
-2,230
| -4% | -$64.9K | 0.85% | 37 |
|
|
2013
Q3 | $1.46M | Buy |
53,718
+153
| +0.3% | +$4.16K | 0.89% | 34 |
|
|
2013
Q2 | $1.42M | Buy |
+53,565
| New | +$1.48M | 0.88% | 34 |
|
Other funds holding PFE
Compton Capital Management's PFE Position: Q2 2023 in Review
Compton Capital Management sold out of Pfizer (PFE) in Q2 2023, closing a stake of 15,931 shares — an estimated $650K sold.
Compton Capital Management first reported a position in PFE in Q2 2013 and held it in 40 quarters. The position peaked at $3.75M in Q4 2021. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.
- Compton Capital Management reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
- Compton Capital Management sold 15,931 Pfizer shares in Q2 2023, an estimated $650K.
- Compton Capital Management first reported a position in Pfizer in Q2 2013 and held it in 40 quarters.
- Compton Capital Management's Pfizer position peaked at $3.75M in Q4 2021.
- 3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.
Based on Compton Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.